ReviewCureus2026
Cutting-Edge Cardiology: Individualizing Antiplatelet Therapy for Optimal Acute Coronary Syndrome Outcomes.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor, is fundamental after percutaneous coronary intervention (PCI) in acute coronary syndromes (ACSs). Recent evidence supports moving from a uniform to an individualized approach, tailoring therapy duration and intensity to patient-specific ischemic and bleeding risks. A targeted literature review was conducted in PubMed, MEDLINE, Scopus, and Google Scholar from inception to June 2025. Relevant MeSH and free-text terms included "acute coronary syndromes, dual antiplatelet therapy, percutaneous coronary intervention, ticagrelor, prasugrel, clopidogrel, de-escalation, abbreviated therapy, rivaroxaban, and dual pathway inhibition." Boolean operators were applied, and studies were restricted to English-language publications in humans. Case reports, small case series, and studies unrelated to ACS populations were excluded. In parallel, a panel of 10 interventional cardiologists from major Lebanese institutions convened in Beirut in 2025. Experts critically appraised global trial data and contextualized recommendations within regional realities of patient risk profiles, drug accessibility, and healthcare infrastructure. Guidelines and pivotal trials endorse tailoring DAPT duration: shortened courses (1-3 months) with P2Y12 monotherapy in high-bleeding-risk patients, extended therapy beyond 12 months or dual-pathway inhibition in high-ischemic-risk patients, and preferential use of ticagrelor or prasugrel over clopidogrel in ACS. Expert consensus emphasized balancing bleeding and ischemic risks, incorporating validated risk scores, and adapting strategies to socioeconomic constraints in Lebanon and the wider MENA (Middle East and North Africa) region. By integrating global evidence with regional expert insights, this review provides a pragmatic framework for precision-based DAPT strategies in ACS, optimizing outcomes while minimizing harm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.